LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

14.93 -2.03

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.65

Max

15.17

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-6.9M

6M

Pardavimai

9.4M

162M

P/E

Sektoriaus vid.

74.2

50.291

Pelno marža

3.676

Darbuotojai

1,811

EBITDA

5.6M

-5M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+35.92% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-153M

2.5B

Ankstesnė atidarymo kaina

16.96

Ankstesnė uždarymo kaina

14.93

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-26 23:49; UTC

Uždarbis

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025-06-26 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025-06-26 21:30; UTC

Uždarbis

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Uždarbis

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025-06-26 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025-06-26 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025-06-26 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025-06-26 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025-06-26 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025-06-26 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025-06-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025-06-26 22:06; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:15; UTC

Uždarbis

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025-06-26 21:07; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025-06-26 21:06; UTC

Rinkos pokalbiai

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 20:52; UTC

Uždarbis

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025-06-26 20:51; UTC

Uždarbis

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025-06-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

35.92% į viršų

12 mėnesių prognozė

Vidutinis 20.85 USD  35.92%

Aukščiausias 27 USD

Žemiausias 14.7 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.